Concept Life Sciences expanded its integrated drug discovery facilities in the U.K., consolidating chemistry, ADMET, and screening biology capabilities to streamline early-stage innovation. Synaffix and Qurient Therapeutics announced a licensing partnership to develop dual-payload ADCs targeting solid tumors, combining advanced antibody conjugation and kinase inhibition technologies. Such collaborations and facility enhancements accelerate therapeutic pipeline progression, enabling efficient translation of breakthrough science into viable treatments.